WATCHLONGEVITY

Sunday, June 21, 2026

Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
Importance
72
Trust
71
Urgency
30
COMMERCIAL

Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure

Novo Nordisk says one million patients are already taking its Wegovy pill version, even though rival Lilly launched its own weight-loss pill called Foundayo. The company reported strong pill sales in the first quarter.

Analysis

Novo's Wegovy pill is reaching lots of patients fast. That matters because Lilly just launched its own weight-loss pill, Foundayo, and the two will now fight for buyers.

  • Novo says one million patients are taking the Wegovy pill version
  • Lilly launched a rival weight-loss pill called Foundayo
  • Novo reported strong pill sales in Q1
$NVO$LLY
WegovyFoundayoNovo NordiskEli Lilly
Endpoints News1mo
Read
BREAKING
Importance
72
Trust
71
Urgency
95
COMMERCIAL

More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says - CNBC

Eli Lilly's CEO said more than 20,000 people are now taking Foundayo, the company's weight-loss pill. The company has not released full sales numbers yet.

Analysis

Lilly's new weight-loss pill is off to a fast start. A pill is easier to take than a shot, which could pull patients away from Novo's drugs.

  • More than 20,000 people are taking Lilly's Foundayo weight-loss pill
  • Lilly CEO shared the user count
  • Full sales figures have not been released yet
$LLY
FoundayoEli Lilly
Novo Nordisk News1mo
Read